AbCellera Biologics Inc.

NASDAQ:ABCL

Biotechnology

Healthcare
$11.02 -0.28%

-$0.02 today

Market cap
$3.60B
Beta
1.20
P/E (TTM)
-11.4
EPS (TTM)
-$0.47
52W Low $2.75High $6.79

Volume 2.58M

Average 6.37M

ABCL Interest Income

Income earned on cash, deposits, and investments held by the company.

AbCellera Biologics Inc.NASDAQ: ABCL

Interest Income · Q3 FY2026 · quarter ended Sep 2026

Interest income remains negative

Q3 FY2026 interest income was $0, compared with $6.77M a year earlier. Trailing-twelve-month interest income was $9.56M. Over 3 fiscal years it compounded at +20.8% a year.

Context

  • Interest income amounted to 37.7% of revenue in FY2025, down 95.7 pp from a year earlier.
  • Interest income increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly interest income holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.39M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$28.33M-26.4% YoY
LTMSep 2026
$9.56M-69.2% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-26.4%——
3-year CAGR+20.8%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
28.33M USD
Year-over-year change
-26.4%
4-year CAGR
+70.8%

Interest Income vs competitors

How ABCL compares with its peers on the latest reported figures

  • ABCL's LTM Sep 2026 interest income of $9.56M is the 3rd highest of the 4 companies compared; the peer median is $13.66M.
  • Its year-over-year change of -69.2% is the lowest of 3, against a peer median of +23.0%.
  • Interest income amounts to 14.1% of revenue for ABCL, versus a peer median of 39.8%.
ABCL Competitors Peer median
Interest Income for ABCL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
DNAGinkgo Bioworks Holdings, Inc.LTM Mar 2026$56.28M +70.6%+3.7%39.8%
GENBGenerate Biomedicines, Inc.FY2025$13.66M -24.6%—42.8%
ABCLAbCellera Biologics Inc.LTM Sep 2026$9.56M -69.2%+20.8%14.1%
ABSIAbsci CorporationLTM Mar 2026$0 ——0.0%
Peer median (excluding ABCL) $13.66M+23.0%+3.7%39.8%

Competitors are the stored peer set for ABCL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue375.2M485.42M38.03M28.83M75.13M
Cost of Revenue45.52M66.44M0028.82M
Gross Profit329.69M418.99M38.03M28.83M46.31M
Gross Margin87.9%86.3%100.0%100.0%61.6%
Research & Development62.06M107.88M175.66M167.26M186.83M
Selling, General & Admin48.76M66.76M75.18M85.49M76.58M
Operating Expenses125.27M202.48M275.23M343.6M263.41M
Depreciation & Amortization17.25M33.1M30.89M97M28.82M
EBITDA239.15M260.17M(192.16M)(204.15M)(148.77M)
EBITDA Margin63.7%53.6%-505.3%-708.0%-198.0%
Operating Income204.41M216.51M(237.21M)(314.77M)(217.1M)
Operating Margin54.5%44.6%-623.8%-1091.7%-289.0%
Interest Income3.33M16.08M42.25M38.47M28.33M
Interest Expense5.23M4.05M000
Other Income / Expenses14.74M22.59M63.18M114.37M39.51M
Income Before Tax219.15M239.1M(174.03M)(200.4M)(177.6M)
Pre-Tax Margin58.4%49.3%-457.7%-695.0%-236.4%
Income Tax Expense65.69M80.58M(27.63M)(37.54M)(31.18M)
Net Income153.46M158.52M(146.4M)(162.86M)(146.41M)
Net Margin40.9%32.7%-385.0%-564.8%-194.9%
EPS (Basic)0.560.56(0.51)(0.55)(0.49)
EPS (Diluted)0.480.50(0.51)(0.55)(0.49)
Weighted Avg Shares275.76M285.06M289.17M294.33M298.71M
Weighted Avg Shares (Diluted)318.29M314.83M289.17M294.33M298.71M

AbCellera Biologics Inc.

NASDAQ:ABCL

Intrinsic Alpha fair value

Locked

Current Price

$11.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.